文献速递关节外科

术前NarxCare过量风险评分大于200与初次全膝关节置换术后1年患者报告结局较差及不满意相关

Preoperative NarxCare Overdose Risk Scores Greater than 200 Are Associated With Worse 1-Year Patient-Reported Outcomes and Dissatisfaction after Primary Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2025-09-01

研究纳入2018至2022年接受初次全膝关节置换术的6710例患者,评估术前NarxCare过量风险评分(ORS)与1年患者报告结局指标(PROMs)临床意义改善及满意度的关联。结果显示,相较ORS为0,较高的ORS与KOOS-JR的MCID失败、KOOS疼痛/PS/JR的PASS失败、1年不满意及KOOS-JR的SCB失败风险升高独立相关。

要点

  • 术前ORS 100-199至400-499与KOOS-JR的MCID失败风险升高相关(OR 1.28-2.27)。
  • ORS 100-199至≥500与KOOS疼痛、PS、JR的PASS失败风险升高相关(OR分别1.23-2.59、1.26-3.87、1.45-2.69)。
  • ORS 100-199至≥500与术后1年不满意相关(OR 1.21-2.85),ORS 100-499与KOOS-JR的SCB失败相关(OR 1.18-1.80)。

核心结论

  • 较高的术前NarxCare ORS与全膝关节置换术后1年疼痛、功能和满意度获得有意义改善的 odds 降低独立相关。

研究设计与样本

  • 纳入2018至2022年在学术医疗系统接受初次全膝关节置换术的患者共6710例。
  • 术前ORS分布:44.8%为0分,28.0%为100-199分,15.1%为200-299分。
  • 采用多变量回归模型评估基线ORS与1年PROMs的关系,以MCID、PASS和SCB阈值判定临床相关改善。

主要发现

  • 相较ORS 0,KOOS-JR的MCID失败风险在ORS 100-199(OR=1.28,P=0.033)、200-299(OR=1.51,P=0.003)、300-399(OR=1.84,P=0.001)和400-499(OR=2.27,P=0.003)升高。
  • 从ORS 100-199至≥500,KOOS疼痛的PASS失败OR为1.23至2.59(P=0.003),KOOS-PS为1.26至3.87(P≤0.001),KOOS-JR为1.45至2.69(P=0.03)。
  • 术后1年不满意与ORS 100-199至≥500相关(OR=1.21至2.85,P≤0.026)。
  • KOOS-JR的SCB失败与ORS 100-499相关(OR=1.18至1.80,P≤0.032)。

临床怎么用

  • 作者认为,这一易于获取的指标可能有助于指导术前咨询,并对美国医疗保险和医疗补助服务中心(Centers for Medicare & Medicaid Services)将报销与PROM表现挂钩的政策演变具有重要意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The NarxCare Overdose Risk Score (ORS) is a measure of prescription drug use with scores ranging from 0 to 999, and higher scores suggest worse prescription drug use patterns, including opioids, sedatives, and stimulants. We aimed to evaluate the association of preoperative NarxCare ORS with clinically meaningful improvements in patient-reported outcome measures (PROMs) and satisfaction at one year. METHODS: Patients undergoing primary total knee arthroplasty at an academic health care system (2018 to 2022) were included. Of 6,710 patients, 44.8% had ORS 0, 28.0% had 100 to 199, and 15.1% had 200 to 299. The PROMs evaluated included the Knee Disability and Osteoarthritis Outcome Score (KOOS) Pain, Physical Function Short Form (PS), and Joint Replacement (JR). Clinically relevant improvements were determined by the minimal clinically important difference (MCID), Patient Acceptable Symptoms State (PASS), and substantial clinical benefit (SCB) thresholds. Multivariable regression models were used to assess the relationship between baseline ORS and 1-year PROMs. RESULTS: Compared to ORS 0, higher ORS was linked to worse outcomes. TheMCID failure for KOOS-JR increased with ORS 100 to 199 (odds ratio (OR) = 1.28, P = 0.033), 200 to 299 (OR = 1.51, P = 0.003), 300 to 399 (OR = 1.84, P = 0.001), and 400 to 499 (OR = 2.27, P = 0.003). The PASS failure rose across KOOS Pain (OR = 1.23 to 2.59, P = 0.003), KOOS -PS (OR = 1.26 to 3.87, P ≤ 0.001), and KOOS-JR (OR = 1.45 to 2.69, P = 0.03) from ORs 100 to 199 to ≥ 500. Dissatisfaction at one year was associated with ORS 100 to 199 to ≥ 500 (OR = 1.21 to 2.85, P ≤ 0.026). The SCB failure for KOOS-JR was linked to ORS 100 to 499 (OR = 1.18 to 1.80, P ≤ 0.032). CONCLUSIONS: Higher preoperative NarxCare ORS is independently associated with reduced odds of achieving meaningful improvements in pain, function, and satisfaction at one year after total knee arthroplasty. This readily available metric may help guide preoperative counseling and has important implications for evolving Centers for Medicare & Medicaid Services policies that tie reimbursement to PROM performance.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Emara AK, Khan ST, Pasqualini I, et al. Preoperative NarxCare Overdose Risk Scores Greater than 200 Are Associated With Worse 1-Year Patient-Reported Outcomes and Dissatisfaction after Primary Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40902686. doi:10.1016/j.arth.2025.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。